Paper Details

  1. Home
  2. Paper Details

A randomized, controlled trial comparing the immunogenecity and safety of a 23-valent pneumococcal polysaccharide vaccination to a repeated dose 13-valent pneumococcal conjugate vaccination in kidney transplant recipients.

Author: AnttilaVeli-Jukka, ErikssonMari, KoskinenPetri, KäyhtyHelena, LahdenkariMika, MäkisaloHeikki, SahaHeikki

Clinical Trial, Phase IVPost-marketing surveillance. Monitors long-term safety/efficacy after approval.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

A study comparing 13-valent pneumococcal conjugate vaccine (PCV13) with 23-valent pneumococcal polysaccharide vaccine (PPV23) in dialysis patients found that PCV13 was more immunogenic and safe. The PCV13 group showed significantly higher geometric mean concentrations (GMCs) for 9/13 serotypes and geometric mean titers (GMTs) for 4/13 serotypes after the first vaccination. Revaccination with PCV13 six months after transplantation was also immunogenic and safe.
Paper Details　
Original Abstract of the Article :
BACKGROUND: The risk of invasive pneumococcal disease is significant among solid organ transplant (SOT) recipients. The optimal pneumococcal vaccination strategy for SOT patients is not known. METHODS: The potential kidney transplant recipients in dialysis were randomized into two arms: to receive ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1111/tid.13343

データ提供：米国国立医学図書館（NLM）

Optimizing Pneumococcal Vaccination in Kidney Transplant Recipients

The field of [Immunology] faces the challenge of protecting vulnerable populations, like [Kidney Transplant Recipients], from infectious diseases. This study aimed to investigate the optimal [Pneumococcal Vaccination] strategy for [Kidney Transplant Recipients] by comparing the effectiveness and safety of [23-valent pneumococcal polysaccharide vaccine (PPV23)] to [repeated dose 13-valent pneumococcal conjugate vaccine (PCV13)]. The researchers conducted a [Randomized Controlled Trial] and found that [PCV13] offered superior immunogenicity and safety compared to [PPV23].

The Importance of Revaccination

The study showed that [Revaccination] with [PCV13] was both immunogenic and safe. This finding is important for [Kidney Transplant Recipients] because it suggests that a two-dose regimen of [PCV13] could provide more robust and longer-lasting protection against pneumococcal disease. The researchers also observed that antibody levels remained higher in the [PCV13] group compared to the [PPV23] group even after six months.

Protecting Vulnerable Populations

These findings provide valuable insights into optimizing [Pneumococcal Vaccination] strategies for [Kidney Transplant Recipients]. By ensuring that these individuals receive the best possible protection, we can reduce their risk of serious complications and improve their overall health. This study highlights the importance of ongoing research and development in the field of [Immunology], especially when it comes to protecting vulnerable populations.

Dr.Camel's Conclusion

The study suggests that a two-dose regimen of PCV13 could provide more robust and longer-lasting protection against pneumococcal disease in kidney transplant recipients. This finding could have significant implications for improving the health of this vulnerable population.

Date :
  1. Date Completed 2021-06-07
  2. Date Revised 2021-08-10
Further Info :

Pubmed ID

32473046

DOI: Digital Object Identifier

10.1111/tid.13343

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.